An ophthalmic therapeutic company in the business of commercializing innovative treatments for age-related eye diseases, including age-related macular degeneration, or AMD, and glaucoma.


Updates from The Motley Fool

Latest updates on TearLab from Fool.com.


Stock Performance

TEAR vs. S&P 500 | 2 Year Performance
View Interactive TEAR Charts
Sponsored by

Key Data Points

Primary metrics and data points about TearLab.
Current Price: $0.86
Prev Close: $0.87
Open: $0.85
Bid: $0.70
Ask: $0.87
Day's Range: $0.79 - $0.90
52wk Range: $0.58 - $3.03
Volume: 274,087
Avg Vol 273,539
Market Cap: $29.03M
P/E (ttm): -0.92
EPS (ttm): -$0.95
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about TearLab.
CAPS Rating 1 out of 5
 
23 Outperform
11 Underperform
CAPS All Stars
 
2 Outperform
6 Underperform

How do you think TearLab will perform against the market?



You pick for TearLab is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Elias Vamvakas, CEO

100% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for TearLab.

An ophthalmic therapeutic company in the business of commercializing innovative treatments for age-related eye diseases, including age-related macular degeneration, or AMD, and glaucoma.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Healthcare IT